List of Cometriq drug patents

Cometriq is owned by Exelixis.

Cometriq contains Cabozantinib S-Malate.

Cometriq has a total of 7 drug patents out of which 0 drug patents have expired.

Cometriq was authorised for market use on 29 November, 2012.

Cometriq is available in capsule;oral dosage forms.

Cometriq can be used as method of treating medullary thyroid cancer.

The generics of Cometriq are possible to be released after 10 February, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS c-Met modulators and methods of use
Aug, 2026

(3 years from now)

US11091439 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(6 years from now)

US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US11091440 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

US11298349 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in